This independent CME/CNE lunch symposium, led by Fred D. Lublin, MD, will analyze therapeutic strategies for improving outcomes and reducing disability in patients with multiple sclerosis (MS). The expert faculty will discuss best practices for early detection and monitoring of disease therapy in the MS patient population. The faculty will debate strategies for selecting and switching therapies in the MS landscape in an interactive panel format. Optimal methods for providing long-term comprehensive care and managing disease progression utilizing the interprofessional team will be reviewed. This CME/CNE program will provide clinicians with vital information for improving outcomes and quality of life in patients with multiple sclerosis.
Neurologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with MS
1. Apply the principles of early diagnosis and early intervention for the management of patients with MS
2. Analyze the most recent evidence-based data of therapeutic options to treat patients with MS
3. Develop optimal treatment strategies for the long-term management of disease progression and the reduction of disability
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD||Consultant/Advisor: AbbVie Inc; Acorda Therapeutics; Actelion Pharmaceuticals US, Inc; Apitope; Atara Biotherapeutics; Bayer AG; Biogen; Brainstorm Cell Therapeutics; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; GW Pharmaceuticals plc.; Innate Immunotherapeutics; Jazz Pharmaceuticals; Mapi Pharma; MedDay Pharmaceuticals; MedImmune; Novartis Pharmaceuticals Corporation; Orion Biotechnology; PolyPharma; Receptos, Inc.; Regeneron; Roche; Sanofi; Teva Pharmaceutical Industries Ltd; TG Therapeutics, Inc.|
Grant/Research Support: National Multiple Sclerosis Society; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd; Transparency Life Sciences; Sanofi
|Joseph R. Berger, MD|
|Consultant/Advisor: Alcimed; Amgen Inc.; AstraZeneca; Bayer AG; Biogen; Bristol-Myers Squibb Company; EMD Serono, Inc.; Eisai, Inc.; Excision BioTherapeutics; Genentech, Inc.; Genzyme Corporation; Inhibikase Therapeutics, Inc.; Johnson and Johnson Services, Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Sanofi; Takeda Pharmaceutical Company Limited|
|Jerry S. Wolinsky, MD||Consultant/Advisor: Alkermes; Acorda Therapeutics; EMD Serono, Inc.; Genentech, Inc.; Genzyme Corporation; GeNeuro; GW Pharmaceuticals plc.; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; Roche; Sanofi|
Grant/Research Support: Millipore (Chemicon International) Corporation
|Peer Reviewer||Relationship Identified With:|
|Suahyl Dhib-Jalbut, MD||Consultant/Advsior: Celgene Corporation|
Grant/Research Support: Biogen
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].